Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- WORLD NEWS IN BRIEF
July 1, 2002
- FPMAJ Proposes Concrete Application Rule for New NHI Pricing Method
July 1, 2002
- Pharmacia to Double Sales, Enter Top 10 in 2005: Mr Yamaki
July 1, 2002
- 46 Active Ingredients Listed for Quality Reevaluation
June 24, 2002
- WORLD NEWS
June 24, 2002
- REGULATORY NEWS IN BRIEF
June 24, 2002
- BULLETIN
June 24, 2002
- MPC to Place Top Priority on Independent Marketing in US
June 24, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
June 24, 2002
- Tsumura Forecasts Rapid Recovery of Business
June 24, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
June 24, 2002
- Sankyo to Conduct Research with Tularik on GPCR Drug Discovery
June 24, 2002
- Ain Pharmaciez Ties Up with Nice Drug of Nagoya
June 24, 2002
- GSK Strengthening Alliance Strategy in Japan
June 24, 2002
- Korosho Urges National Hospitals to Use More Generics
June 24, 2002
- Toho to Exchange Business with 3 Local Wholesalers
June 24, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 24, 2002
- Univ. of Tokyo Introduces SNP Typing System from Olympus
June 24, 2002
- Matsumotokiyoshi to Restart Aggressive Store Opening
June 24, 2002
- WEBSITE NEWS
June 24, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…